Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow REPLIGEN CORP

Get SEC filing alerts via email and in your feed for REPLIGEN CORP

RGEN

REPLIGEN CORP

About REPLIGEN CORP

Repligen is a global life sciences company specializing in innovative bioprocessing technologies and systems that enhance the efficiency, scalability, and flexibility of biologic drug manufacturing. Its core offerings include filtration, chromatography, process analytics, and proteins, serving biopharmaceutical, gene therapy, and vaccine markets. The company focuses on integrated solutions, continuous innovation, and strategic acquisitions to support biologics, mRNA, and gene therapy production worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from REPLIGEN CORP

1
1
REPLIGEN CORP Repligen Corporation Reports 14.8% Revenue Growth to $194.3 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
REPLIGEN CORP Repligen Corporation Reports 16.4% Revenue Growth to $738.3 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
REPLIGEN CORP Repligen Corporation Reports 21.9% Revenue Growth and Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
REPLIGEN CORP Repligen Corporation Reports 14.8% Revenue Growth to $182.4 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
REPLIGEN CORP Repligen Corporation Reports $169.2 Million Revenue in Q1 2025, Driven by Product Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
REPLIGEN CORP Repligen Corporation Reports Modest Revenue Increase to $634.4 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
REPLIGEN CORP Repligen Reports 9.7% Revenue Growth, Net Loss in Q3 2024, Amid Strategic Developments and Financial Adjustments

Via official filing (AI summary) | over 1 year ago | 0 comments